Immunotherapeutic restoration in HIV-infected individuals

被引：5

作者：

Kim, June Myung ^{[1
,2
]}

Han, Sang Hoon ^{[1
,2
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea

[2] Yonsei Univ, Coll Med, AIDS Res Inst, Seoul 120752, South Korea

来源：

IMMUNOTHERAPY | 2011年 / 3卷 / 02期

关键词：

cytokine therapy; HIV; immune-modulating drugs; immunotherapy; monoclonal antibodies; nanotechnology-based approaches; radioimmunotherapy; therapeutic immunization; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CCR5; MONOCLONAL-ANTIBODY; CHRONIC VIRAL-INFECTION; CD4(+) T-CELLS; INTERMITTENT INTERLEUKIN-2 THERAPY; DOSE SUBCUTANEOUS INTERLEUKIN-2; CELLULAR IMMUNE-RESPONSES; DENDRITIC CELLS;

D O I：

10.2217/IMT.10.91

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

While the development of combined active antiretroviral therapy (cART) has dramatically improved life expectancies and quality of life in HIV-infected individuals, long-term clinical problems, such as metabolic complications, remain important constraints of life-long cART. Complete immune restoration using only cART is normally unattainable even in cases of sufficient plasma viral suppression. The need for immunologic adjuncts that complement cART remains, because while cART alone may result in the complete recovery of peripheral net CDC(+) T lymphocytes, it may not affect the reservoir of HIV-infected cells. Here, we review current immunotherapies for HIV infection, with a particular emphasis on recent advances in cytokine therapies, therapeutic immunization, monoclonal antibodies, immune-modulating drugs, nanotechnology-based approaches and radioimmunotherapy.

引用

页码：247 / 267

页数：21

共 175 条

[21] Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: Role of phosphate-binding subsites [J].

Brown, Bruce K. ;

Karasavvas, Nicos ;

Beck, Zoltan ;

Matyas, Gary R. ;

Birx, Deborah L. ;

Polonis, Victoria R. ;

Alving, Carl R. .

JOURNAL OF VIROLOGY, 2007, 81 (04) :2087-2091

[22] Antibody vs. HIV in a clash of evolutionary titans [J].

Burton, DR ;

Stanfield, RL ;

Wilson, IA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (42) :14943-14948

[23] IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine [J].

Calarota, Sandra A. ;

Dai, Anlan ;

Trocio, Jeffrey N. ;

Weiner, David B. ;

Lori, Franco ;

Lisziewicz, Julianna .

VACCINE, 2008, 26 (40) :5188-5195

[24] Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study [J].

Carr, A ;

Emery, S ;

Lloyd, A ;

Hoy, J ;

Garsia, R ;

French, M ;

Stewart, G ;

Fyfe, G ;

Cooper, DA .

JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (04) :992-999

[25] Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120 [J].

Cavacini, LA ;

Samore, MH ;

Gambertoglio, J ;

Jackson, B ;

Duval, M ;

Wisnewski, A ;

Hammer, S ;

Koziel, C ;

Trapnell, C ;

Posner, MR .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (07) :545-550

[26] Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo [J].

Chapuis, AG ;

Rizzardi, GP ;

D'Agostino, C ;

Attinger, A ;

Knabenhans, C ;

Fleury, S ;

Acha-Orbea, H ;

Pantaleo, G .

NATURE MEDICINE, 2000, 6 (07) :762-768

[27] Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV89.6P challenge in rhesus macaques [J].

Chong, Siew-Yen ;

Egan, Michael A. ;

Kutzler, Michele A. ;

Megati, Shakuntala ;

Masood, Amjed ;

Roopchard, Vidia ;

Garcia-Hand, Dorys ;

Montefiori, David C. ;

Quiroz, Jorge ;

Rosati, Margherita ;

Schadeck, Eva B. ;

Boyer, Jean D. ;

Pavlakis, George N. ;

Weiner, David B. ;

Sidhu, Maninder ;

Eldridge, John H. ;

Israel, Zimra R. .

VACCINE, 2007, 25 (26) :4967-4982

[28] The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C [J].

Cilliers, T ;

Nhlapo, J ;

Coetzer, M ;

Orlovic, D ;

Ketas, T ;

Olson, WC ;

Moore, JP ;

Trkola, A ;

Morris, L .

JOURNAL OF VIROLOGY, 2003, 77 (07) :4449-4456

[29] Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp 120 human IgG1 κ monoclonal antibody, in HIV-1 infected cells [J].

Clayton, Reginald ;

Ohagen, Asa ;

Goethals, Olivia ;

Smets, Alexandra ;

Van Loock, Marnix ;

Michiels, Lieve ;

Kennedy-Johnston, Erin ;

Cunningham, Mark ;

Jiang, Haiyan ;

Bola, Sharon ;

Gutshall, Lester ;

Gunn, George ;

Del Vecchio, Alfred ;

Sarisky, Robert ;

Hallenberger, Sabine ;

Hertogs, Kurt .

JOURNAL OF VIROLOGICAL METHODS, 2007, 139 (01) :17-23

[30] Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-Infected individuals [J].

Connolly, Nancy C. ;

Whiteside, Theresa L. ;

Wilson, Cara ;

Kondragunta, Venkatswarlu ;

Rinaldo, Charles R. ;

Riddler, Sharon A. .

CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (02) :284-292

← 1 2 3 4 5 6 7 8 9 10 →